This is in line with studies showing that targeting the PI3K/Akt/mTOR pathway represses stem-like cell properties in GBM cells by reducing the expression of other pluripotency-regulating transcription factors, such as NANOG and OCT-4 [116,117,118]. The gene discussed is AKT1; the disease is glioblastoma.